Protagonist Therapeutics, Inc. <PTGX.O>: BMO raises target price to $178 from $112
PTGX•Related News
Fed to hold interest rates this year, economists say, sticking to their view
TLT•
Resideo CEO Thomas Surran buys 15,000 shares for $306,900
REZI•
Faeth Therapeutics wins FDA fast-track status for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer
FTH•
Alaska Air Group Inc cuts price objective to $60 from $65
ALK•
Duke Energy Corp <DUK.N>: Truist Securities cuts target price to $135 from $138
DUK•